FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:EGFR-ERP44 (FusionGDB2 ID:25431)

Fusion Gene Summary for EGFR-ERP44

check button Fusion gene summary
Fusion gene informationFusion gene name: EGFR-ERP44
Fusion gene ID: 25431
HgeneTgene
Gene symbol

EGFR

ERP44

Gene ID

1956

23071

Gene nameepidermal growth factor receptorendoplasmic reticulum protein 44
SynonymsERBB|ERBB1|HER1|NISBD2|PIG61|mENAPDIA10|TXNDC4
Cytomap

7p11.2

9q31.1

Type of geneprotein-codingprotein-coding
Descriptionepidermal growth factor receptoravian erythroblastic leukemia viral (v-erb-b) oncogene homologcell growth inhibiting protein 40cell proliferation-inducing protein 61epidermal growth factor receptor tyrosine kinase domainerb-b2 receptor tyrosine kinasendoplasmic reticulum resident protein 44ER protein 44endoplasmic reticulum resident protein 44 kDaepididymis secretory sperm binding proteinprotein disulfide isomerase family A, member 10thioredoxin domain containing 4 (endoplasmic reticulum)thiore
Modification date2020032920200313
UniProtAcc

P00533

Q9BS26

Ensembl transtripts involved in fusion geneENST00000455089, ENST00000342916, 
ENST00000344576, ENST00000420316, 
ENST00000275493, ENST00000442591, 
ENST00000463948, ENST00000454757, 
ENST00000262455, 
Fusion gene scores* DoF score41 X 25 X 14=143507 X 5 X 5=175
# samples 537
** MAII scorelog2(53/14350*10)=-4.75891456699985
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(7/175*10)=-1.32192809488736
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: EGFR [Title/Abstract] AND ERP44 [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointEGFR(55087058)-ERP44(102784508), # samples:2
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneEGFR

GO:0001934

positive regulation of protein phosphorylation

20551055

HgeneEGFR

GO:0007165

signal transduction

10572067

HgeneEGFR

GO:0007166

cell surface receptor signaling pathway

7736574

HgeneEGFR

GO:0007173

epidermal growth factor receptor signaling pathway

7736574|12435727

HgeneEGFR

GO:0008283

cell proliferation

17115032

HgeneEGFR

GO:0008284

positive regulation of cell proliferation

7736574

HgeneEGFR

GO:0010750

positive regulation of nitric oxide mediated signal transduction

12828935

HgeneEGFR

GO:0018108

peptidyl-tyrosine phosphorylation

22732145

HgeneEGFR

GO:0030307

positive regulation of cell growth

15467833

HgeneEGFR

GO:0042177

negative regulation of protein catabolic process

17115032

HgeneEGFR

GO:0042327

positive regulation of phosphorylation

15082764

HgeneEGFR

GO:0043406

positive regulation of MAP kinase activity

10572067

HgeneEGFR

GO:0045739

positive regulation of DNA repair

17115032

HgeneEGFR

GO:0045740

positive regulation of DNA replication

17115032

HgeneEGFR

GO:0045944

positive regulation of transcription by RNA polymerase II

20551055

HgeneEGFR

GO:0050679

positive regulation of epithelial cell proliferation

10572067

HgeneEGFR

GO:0050999

regulation of nitric-oxide synthase activity

12828935

HgeneEGFR

GO:0070141

response to UV-A

18483258

HgeneEGFR

GO:0070374

positive regulation of ERK1 and ERK2 cascade

20551055

HgeneEGFR

GO:0071392

cellular response to estradiol stimulus

20551055

HgeneEGFR

GO:1900020

positive regulation of protein kinase C activity

22732145

HgeneEGFR

GO:1903078

positive regulation of protein localization to plasma membrane

22732145

TgeneERP44

GO:0006457

protein folding

11847130

TgeneERP44

GO:0006986

response to unfolded protein

11847130

TgeneERP44

GO:0009100

glycoprotein metabolic process

11847130

TgeneERP44

GO:0034976

response to endoplasmic reticulum stress

11847130


check buttonFusion gene breakpoints across EGFR (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check buttonFusion gene breakpoints across ERP44 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4GBMTCGA-06-0744EGFRchr7

55087058

+ERP44chr9

102784508

-
ChimerDB4GBMTCGA-06-0744-01AEGFRchr7

55087058

-ERP44chr9

102784508

-


Top

Fusion Gene ORF analysis for EGFR-ERP44

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
In-frameENST00000455089ENST00000262455EGFRchr7

55087058

+ERP44chr9

102784508

-
In-frameENST00000342916ENST00000262455EGFRchr7

55087058

+ERP44chr9

102784508

-
In-frameENST00000344576ENST00000262455EGFRchr7

55087058

+ERP44chr9

102784508

-
In-frameENST00000420316ENST00000262455EGFRchr7

55087058

+ERP44chr9

102784508

-
In-frameENST00000275493ENST00000262455EGFRchr7

55087058

+ERP44chr9

102784508

-
In-frameENST00000442591ENST00000262455EGFRchr7

55087058

+ERP44chr9

102784508

-
3UTR-3CDSENST00000463948ENST00000262455EGFRchr7

55087058

+ERP44chr9

102784508

-
intron-3CDSENST00000454757ENST00000262455EGFRchr7

55087058

+ERP44chr9

102784508

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000455089EGFRchr755087058+ENST00000262455ERP44chr9102784508-47133452571279340
ENST00000342916EGFRchr755087058+ENST00000262455ERP44chr9102784508-47023342461268340
ENST00000344576EGFRchr755087058+ENST00000262455ERP44chr9102784508-47013332451267340
ENST00000420316EGFRchr755087058+ENST00000262455ERP44chr9102784508-47003322441266340
ENST00000275493EGFRchr755087058+ENST00000262455ERP44chr9102784508-46332651771199340
ENST00000442591EGFRchr755087058+ENST00000262455ERP44chr9102784508-46162481601182340

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000455089ENST00000262455EGFRchr755087058+ERP44chr9102784508-4.62E-050.99995387
ENST00000342916ENST00000262455EGFRchr755087058+ERP44chr9102784508-4.60E-050.999954
ENST00000344576ENST00000262455EGFRchr755087058+ERP44chr9102784508-4.59E-050.9999541
ENST00000420316ENST00000262455EGFRchr755087058+ERP44chr9102784508-4.60E-050.999954
ENST00000275493ENST00000262455EGFRchr755087058+ERP44chr9102784508-4.39E-050.99995613
ENST00000442591ENST00000262455EGFRchr755087058+ERP44chr9102784508-4.29E-050.9999571

Top

Fusion Genomic Features for EGFR-ERP44


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for EGFR-ERP44


check button Go to

FGviewer for the breakpoints of chr7:55087058-chr9:102784508

.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
EGFR

P00533

ERP44

Q9BS26

FUNCTION: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704, PubMed:17909029). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). {ECO:0000250|UniProtKB:Q01279, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11602604, ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15611079, ECO:0000269|PubMed:17115032, ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:27153536, ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:7679104, ECO:0000269|PubMed:8144591, ECO:0000269|PubMed:9419975}.; FUNCTION: Isoform 2 may act as an antagonist of EGF action.; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins. {ECO:0000269|PubMed:21516087}.FUNCTION: Mediates thiol-dependent retention in the early secretory pathway, forming mixed disulfides with substrate proteins through its conserved CRFS motif. Inhibits the calcium channel activity of ITPR1. May have a role in the control of oxidative protein folding in the endoplasmic reticulum. Required to retain ERO1A and ERO1B in the endoplasmic reticulum. {ECO:0000269|PubMed:11847130, ECO:0000269|PubMed:14517240}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneERP44chr7:55087058chr9:102784508ENST00000262455312403_40695.33333333333333407.0MotifPrevents secretion from ER

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+128712_97929.3333333333333321211.0DomainProtein kinase
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+116712_97929.333333333333332629.0DomainProtein kinase
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+116712_97929.333333333333332706.0DomainProtein kinase
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+110712_97929.333333333333332406.0DomainProtein kinase
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+128718_72629.3333333333333321211.0Nucleotide bindingATP
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+128790_79129.3333333333333321211.0Nucleotide bindingATP
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+116718_72629.333333333333332629.0Nucleotide bindingATP
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+116790_79129.333333333333332629.0Nucleotide bindingATP
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+116718_72629.333333333333332706.0Nucleotide bindingATP
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+116790_79129.333333333333332706.0Nucleotide bindingATP
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+110718_72629.333333333333332406.0Nucleotide bindingATP
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+110790_79129.333333333333332406.0Nucleotide bindingATP
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+128688_70429.3333333333333321211.0RegionNote=Important for dimerization%2C phosphorylation and activation
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+116688_70429.333333333333332629.0RegionNote=Important for dimerization%2C phosphorylation and activation
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+116688_70429.333333333333332706.0RegionNote=Important for dimerization%2C phosphorylation and activation
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+110688_70429.333333333333332406.0RegionNote=Important for dimerization%2C phosphorylation and activation
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+128390_60029.3333333333333321211.0RepeatNote=Approximate
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+12875_30029.3333333333333321211.0RepeatNote=Approximate
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+116390_60029.333333333333332629.0RepeatNote=Approximate
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+11675_30029.333333333333332629.0RepeatNote=Approximate
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+116390_60029.333333333333332706.0RepeatNote=Approximate
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+11675_30029.333333333333332706.0RepeatNote=Approximate
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+110390_60029.333333333333332406.0RepeatNote=Approximate
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+11075_30029.333333333333332406.0RepeatNote=Approximate
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+12825_64529.3333333333333321211.0Topological domainExtracellular
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+128669_121029.3333333333333321211.0Topological domainCytoplasmic
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+11625_64529.333333333333332629.0Topological domainExtracellular
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+116669_121029.333333333333332629.0Topological domainCytoplasmic
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+11625_64529.333333333333332706.0Topological domainExtracellular
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+116669_121029.333333333333332706.0Topological domainCytoplasmic
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+11025_64529.333333333333332406.0Topological domainExtracellular
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+110669_121029.333333333333332406.0Topological domainCytoplasmic
HgeneEGFRchr7:55087058chr9:102784508ENST00000275493+128646_66829.3333333333333321211.0TransmembraneHelical
HgeneEGFRchr7:55087058chr9:102784508ENST00000342916+116646_66829.333333333333332629.0TransmembraneHelical
HgeneEGFRchr7:55087058chr9:102784508ENST00000344576+116646_66829.333333333333332706.0TransmembraneHelical
HgeneEGFRchr7:55087058chr9:102784508ENST00000420316+110646_66829.333333333333332406.0TransmembraneHelical
TgeneERP44chr7:55087058chr9:102784508ENST0000026245531230_13895.33333333333333407.0DomainThioredoxin


Top

Fusion Gene Sequence for EGFR-ERP44


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>In-frame_ENST00000455089_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(transcript)=4713nt_BP=345nt
GTCCGGGCAGCCCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGCCGAGGCGGCCGGAGTCC
CGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCC
ACAACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCG
GGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGCTGACATAGCCCAGA
GATACAGGATAAGCAAATACCCAACCCTCAAATTGTTTCGTAATGGGATGATGATGAAGAGAGAATACAGGGGTCAGCGATCAGTGAAAG
CATTGGCAGATTACATCAGGCAACAAAAAAGTGACCCCATTCAAGAAATTCGGGACTTAGCAGAAATCACCACTCTTGATCGCAGCAAAA
GAAATATCATTGGATATTTTGAGCAAAAGGACTCGGACAACTATAGAGTTTTTGAACGAGTAGCGAATATTTTGCATGATGACTGTGCCT
TTCTTTCTGCATTTGGGGATGTTTCAAAACCGGAAAGATATAGTGGCGACAACATAATCTACAAACCACCAGGGCATTCTGCTCCGGATA
TGGTGTACTTGGGAGCTATGACAAATTTTGATGTGACTTACAATTGGATTCAAGATAAATGTGTTCCTCTTGTCCGAGAAATAACATTTG
AAAATGGAGAGGAATTGACAGAAGAAGGACTGCCTTTTCTCATACTCTTTCACATGAAAGAAGATACAGAAAGTTTAGAAATATTCCAGA
ATGAAGTAGCTCGGCAATTAATAAGTGAAAAAGGTACAATAAACTTTTTACATGCCGATTGTGACAAATTTAGACATCCTCTTCTGCACA
TACAGAAAACTCCAGCAGATTGTCCTGTAATCGCTATTGACAGCTTTAGGCATATGTATGTGTTTGGAGACTTCAAAGATGTATTAATTC
CTGGAAAACTCAAGCAATTCGTATTTGACTTACATTCTGGAAAACTGCACAGAGAATTCCATCATGGACCTGACCCAACTGATACAGCCC
CAGGAGAGCAAGCCCAAGATGTAGCAAGCAGTCCACCTGAGAGCTCCTTCCAGAAACTAGCACCCAGTGAATATAGGTATACTCTATTGA
GGGATCGAGATGAGCTTTAAAAACTTGAAAAACAGTTTGTAAGCCTTTCAACAGCAGCATCAACCTACGTGGTGGAAATAGTAAACCTAT
ATTTTCATAATTCTATGTGTATTTTTATTTTGAATAAACAGAAAGAAATTTTGGGTTTTTAATTTTTTTCTCCCCGACTCAAAATGCATT
GTCATTTAATATAGTAGCCTCTTAAAAAAAAAAAACCTGCTAGGATTTAAAAATAAAAATCAGAGGCCTATCTCCACTTTAAATCTGTCC
TGTAAAAGTTTTATAAATCAAATGAAAGGTGACATTGCCAGAAACTTACCATTAACTTGCACTACTAGGGTAGGGAGGACTTAGGGATGT
TTCCTGTGTCGTATGTGCTTTTCTTTCTTTCATATGATCAATTCTGTTGGTATTTTCAGTATCTCATTTCTCAAAGCTAAAGAGATATAC
ATTCTGGATACTTGGGAGGGGAATAAATTAAAGTTTTCACACTGTGTACTGTGTTTTACTGATTGGTTGGATATTGCTTATGAAAATTCC
ATAGTGGTATTTTTTTGGATTCTTAATGTGTAACTTAAACATACTTTGAAGTGGAGGAGAGTCATAAGACAGAACATTTGGCAGGAATTG
TCCTTATGAAACAAGAAAAAGAAAATGAAAAGTATTATTAAGCTTCTGTGTTTGTCTAAAAATGTGGCATATGGATGGCATTTAAAACTT
TGAATGAATTATACCTAAATCTGGGACAGGGAGGTGACAGTGGAACAGGCTACCAATCAGAACTAGATGACTTTTAAGGCTCCTCCTATT
ATGAGACTTCAATTTCCAAAGAGAAGAACTAGCAGAGAAATTGTATTTCAGTAATTTTAAGCTCCTTCTGTCTTGTAGAGTCTTGTTATA
GTTGTATAAATCAAAAACACAGAATAAGGAACATATTTAACTTTTTTTCATTATAAAATGGTTAGAGGACCCTACCCCCTCTAGATTCCC
TGATTTCCCCAGGCCTGCAGCATACAGTAAGATGGGTCCCTGTGCCAGGCCTCAATACTGCCAGGGAATAAAACCAGAGGGAGAGGACCC
TCAGTGTCATATCAGGAAGCCCAGTGCCAGAGGACAGACAGGTTCAAAACTGGCTTTTCCTCTGGGCCTGGGTTGGTGCTATAGGCCAAG
GGTCATTTTATACTTGGGTATAAATCAATCCCAGTTTGGGAAAAGATTATTTTTAAGCTTAAAAGGCTGACATGTGCCATTATATGTAGT
ATGTAATATATGTAACATCTTCCAATTCTTTTAAAATAAAATTAATATTTATAATGGATATTTAATGATTGTTATTTTTAAAAACCAGCT
TATAATTCCTCGTTATGCATGATTTATCCAAAGTTTCCATAGTTTTATTCAAAATAATAAATGTTAATAAGGTGATAAGGGGTATATTTA
ATGTATTGTATCAAATTGTGAATAAGAAAGTAGGATGGAGCTTTCTAGAGGTTGGGCCTTAGTTCTGTTATCCTCATTGCTTTTAACCAA
TAAGTTAAATGAAGTTAGAGTTATGGTCTTCAGGTTAGATTATGGACCAGATCTGTGAGGGTCAGCATGGAAATTCACATTCAACAAGGT
AGCACACAGGACCAAGAGCAGCACATGCAATCAACTGGAATAATATAGTAATCCTGTAACTGGGTTTGAAAAAATAATCAACAAAAGATA
CAATTCAAGGGTTAGGTTGCAGAGAGCTGGCTTGAGAGTAGTTATTATGAAAAAGGCCTCAAGGAGTACGTGTTCAGTATGCTCTAAGAT
GATAAAGTGGCTGTTAAAAAGGGAGTTGATTTGAGGAAGTATTACTTAGCATTCATGCATATTGGGCTTAGGCTCTAGCCCTGCCACTAT
CATTGTCTTCTCTGGACTGTGAAGTCACTGAGGACAAGGAAACTAAATTTAATGTCTGTATCACTAGTGCCTAGAATTTCTGGACACTTA
GTAGTCACCATCAGGCGTTTATTTAATGAATGAGAAGCAAAGTGACCTTGGTTACTTTTTTACCCTGAGGGGCTCAGCACTCATTAGGAC
TTGGTGCCTAATTTTATAAAAAGTCACTAAGCTCAAGTGCTTGGATGAAAGGACAGCGTGGATAAAAAGGTTTTTAAAACATGGATGTTA
AGGCTGTTTTGCTTGGAGAAGACTTGGGACTGGGACAGTCTTTAGATATTATTTGAAATGCTGGCACTGTCTATCTGGATCCCAGGGCTT
GAACTAGGATTTGAGGAAGTCACAGGGAAGCAGATTTCAGTCTGACATTTATTCAGTGCAAGTTTTTTGGTGCTGTAGTATATGATGAAA
GATGTAAAGCTGAATAAAGCATTATTTCTGCCCTAGAGTTGTTCACAGCCTAGTCAGGCATATGGATATGTAAACAATGACTGTAACGTG
TTATAGATGTAAAGACAAAATAAAGGTTAAAGAGGGCATAAAGGAGCACTCAATTGCAGAGATTTGAGGACATTATTTTTATTTTGAGCT
TTAAAAAGATGAATAGGTGTTCTCAGGAGGTAGGGATCTGGCTGAGAGGGAATAATCTGAGCAAAGGTATGAAACAGCCTAATGCATTAG
AGAAAAAAGTTCTTTTAGTAAGGCATTTGGGGTTGGGGAAGCTAGAAAAAGAAATGGGAGCTGGTCACACAGGGCCTTGTGTGCCAGACT
AAGGGGTTTGTAGTATATATTGTAGGCAGAAGAGATCCATCAACAGATTGCAAGCAAGGAAGTATGTTCACTTTAAAGTTTGAGAAAGAA
TAGTGTGGAAGCACGTCTCAAATTTAGACTTGTTCCCCCTCTGAACCGTGAATCAGACCATTTCAGGTAGAAGTCTTCCCCGGTTTATCT
GATCTACTCGGGGCCTCAGGCTTCTCAGCTGGGAAGAGAGGATGCAAGACCAGACTGAAGAACACGGTTGAGTCCCCAGAACCAAAAGGG
GGCCTTTCTGCTTCTTAGCCAGCTACCTCTTCGAGTTTTTCAAATTGTGAGGGGGACCATAAAAGGATGGAAACTTTTAGATGACATTCT
ACAAATTATTTTTTTCTTTAAATTAAAAGAACCTAGCCAATAAGATAGAGAATGGGCATCTAAGGCATCTCAGAGCTCTCTGATGAAGCC
AGGTTGTCAAAGATCATTTGCAAAAGAAGGGAAAACTGGCATGACAAAAGCTACAGAGAGGAGAGTGAAATATAGAAGTGTTTGAAATGT
TCAAGCTCACAATAAGCTTAAATTTATAGAAAATGCTAAGGTTGTCAAGAAGGCTTTTTTTTTTTTCTTTTTTAAACCTGAGGGCAAAAA
GGAATGGATAAAGTAGTGTAATGGATTGACAATCAGGAAGAACAGAATAACTCAGTTTTTTTTCTCCTACAAGGAGATATGGCTGGACCA

>In-frame_ENST00000455089_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(amino acids)=340AA_start in transcript=257_stop in transcript=1279
MRPSGTAGAALLALLAALCPASRALEEKKADIAQRYRISKYPTLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLAEITTL
DRSKRNIIGYFEQKDSDNYRVFERVANILHDDCAFLSAFGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWIQDKCVPLVR
EITFENGEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAIDSFRHMYVFGDFK

--------------------------------------------------------------
>In-frame_ENST00000342916_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(transcript)=4702nt_BP=334nt
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCC
CGGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCACCGC
GCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGCCGGG
GCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGCTGACATAGCCCAGAGATACAGGATA
AGCAAATACCCAACCCTCAAATTGTTTCGTAATGGGATGATGATGAAGAGAGAATACAGGGGTCAGCGATCAGTGAAAGCATTGGCAGAT
TACATCAGGCAACAAAAAAGTGACCCCATTCAAGAAATTCGGGACTTAGCAGAAATCACCACTCTTGATCGCAGCAAAAGAAATATCATT
GGATATTTTGAGCAAAAGGACTCGGACAACTATAGAGTTTTTGAACGAGTAGCGAATATTTTGCATGATGACTGTGCCTTTCTTTCTGCA
TTTGGGGATGTTTCAAAACCGGAAAGATATAGTGGCGACAACATAATCTACAAACCACCAGGGCATTCTGCTCCGGATATGGTGTACTTG
GGAGCTATGACAAATTTTGATGTGACTTACAATTGGATTCAAGATAAATGTGTTCCTCTTGTCCGAGAAATAACATTTGAAAATGGAGAG
GAATTGACAGAAGAAGGACTGCCTTTTCTCATACTCTTTCACATGAAAGAAGATACAGAAAGTTTAGAAATATTCCAGAATGAAGTAGCT
CGGCAATTAATAAGTGAAAAAGGTACAATAAACTTTTTACATGCCGATTGTGACAAATTTAGACATCCTCTTCTGCACATACAGAAAACT
CCAGCAGATTGTCCTGTAATCGCTATTGACAGCTTTAGGCATATGTATGTGTTTGGAGACTTCAAAGATGTATTAATTCCTGGAAAACTC
AAGCAATTCGTATTTGACTTACATTCTGGAAAACTGCACAGAGAATTCCATCATGGACCTGACCCAACTGATACAGCCCCAGGAGAGCAA
GCCCAAGATGTAGCAAGCAGTCCACCTGAGAGCTCCTTCCAGAAACTAGCACCCAGTGAATATAGGTATACTCTATTGAGGGATCGAGAT
GAGCTTTAAAAACTTGAAAAACAGTTTGTAAGCCTTTCAACAGCAGCATCAACCTACGTGGTGGAAATAGTAAACCTATATTTTCATAAT
TCTATGTGTATTTTTATTTTGAATAAACAGAAAGAAATTTTGGGTTTTTAATTTTTTTCTCCCCGACTCAAAATGCATTGTCATTTAATA
TAGTAGCCTCTTAAAAAAAAAAAACCTGCTAGGATTTAAAAATAAAAATCAGAGGCCTATCTCCACTTTAAATCTGTCCTGTAAAAGTTT
TATAAATCAAATGAAAGGTGACATTGCCAGAAACTTACCATTAACTTGCACTACTAGGGTAGGGAGGACTTAGGGATGTTTCCTGTGTCG
TATGTGCTTTTCTTTCTTTCATATGATCAATTCTGTTGGTATTTTCAGTATCTCATTTCTCAAAGCTAAAGAGATATACATTCTGGATAC
TTGGGAGGGGAATAAATTAAAGTTTTCACACTGTGTACTGTGTTTTACTGATTGGTTGGATATTGCTTATGAAAATTCCATAGTGGTATT
TTTTTGGATTCTTAATGTGTAACTTAAACATACTTTGAAGTGGAGGAGAGTCATAAGACAGAACATTTGGCAGGAATTGTCCTTATGAAA
CAAGAAAAAGAAAATGAAAAGTATTATTAAGCTTCTGTGTTTGTCTAAAAATGTGGCATATGGATGGCATTTAAAACTTTGAATGAATTA
TACCTAAATCTGGGACAGGGAGGTGACAGTGGAACAGGCTACCAATCAGAACTAGATGACTTTTAAGGCTCCTCCTATTATGAGACTTCA
ATTTCCAAAGAGAAGAACTAGCAGAGAAATTGTATTTCAGTAATTTTAAGCTCCTTCTGTCTTGTAGAGTCTTGTTATAGTTGTATAAAT
CAAAAACACAGAATAAGGAACATATTTAACTTTTTTTCATTATAAAATGGTTAGAGGACCCTACCCCCTCTAGATTCCCTGATTTCCCCA
GGCCTGCAGCATACAGTAAGATGGGTCCCTGTGCCAGGCCTCAATACTGCCAGGGAATAAAACCAGAGGGAGAGGACCCTCAGTGTCATA
TCAGGAAGCCCAGTGCCAGAGGACAGACAGGTTCAAAACTGGCTTTTCCTCTGGGCCTGGGTTGGTGCTATAGGCCAAGGGTCATTTTAT
ACTTGGGTATAAATCAATCCCAGTTTGGGAAAAGATTATTTTTAAGCTTAAAAGGCTGACATGTGCCATTATATGTAGTATGTAATATAT
GTAACATCTTCCAATTCTTTTAAAATAAAATTAATATTTATAATGGATATTTAATGATTGTTATTTTTAAAAACCAGCTTATAATTCCTC
GTTATGCATGATTTATCCAAAGTTTCCATAGTTTTATTCAAAATAATAAATGTTAATAAGGTGATAAGGGGTATATTTAATGTATTGTAT
CAAATTGTGAATAAGAAAGTAGGATGGAGCTTTCTAGAGGTTGGGCCTTAGTTCTGTTATCCTCATTGCTTTTAACCAATAAGTTAAATG
AAGTTAGAGTTATGGTCTTCAGGTTAGATTATGGACCAGATCTGTGAGGGTCAGCATGGAAATTCACATTCAACAAGGTAGCACACAGGA
CCAAGAGCAGCACATGCAATCAACTGGAATAATATAGTAATCCTGTAACTGGGTTTGAAAAAATAATCAACAAAAGATACAATTCAAGGG
TTAGGTTGCAGAGAGCTGGCTTGAGAGTAGTTATTATGAAAAAGGCCTCAAGGAGTACGTGTTCAGTATGCTCTAAGATGATAAAGTGGC
TGTTAAAAAGGGAGTTGATTTGAGGAAGTATTACTTAGCATTCATGCATATTGGGCTTAGGCTCTAGCCCTGCCACTATCATTGTCTTCT
CTGGACTGTGAAGTCACTGAGGACAAGGAAACTAAATTTAATGTCTGTATCACTAGTGCCTAGAATTTCTGGACACTTAGTAGTCACCAT
CAGGCGTTTATTTAATGAATGAGAAGCAAAGTGACCTTGGTTACTTTTTTACCCTGAGGGGCTCAGCACTCATTAGGACTTGGTGCCTAA
TTTTATAAAAAGTCACTAAGCTCAAGTGCTTGGATGAAAGGACAGCGTGGATAAAAAGGTTTTTAAAACATGGATGTTAAGGCTGTTTTG
CTTGGAGAAGACTTGGGACTGGGACAGTCTTTAGATATTATTTGAAATGCTGGCACTGTCTATCTGGATCCCAGGGCTTGAACTAGGATT
TGAGGAAGTCACAGGGAAGCAGATTTCAGTCTGACATTTATTCAGTGCAAGTTTTTTGGTGCTGTAGTATATGATGAAAGATGTAAAGCT
GAATAAAGCATTATTTCTGCCCTAGAGTTGTTCACAGCCTAGTCAGGCATATGGATATGTAAACAATGACTGTAACGTGTTATAGATGTA
AAGACAAAATAAAGGTTAAAGAGGGCATAAAGGAGCACTCAATTGCAGAGATTTGAGGACATTATTTTTATTTTGAGCTTTAAAAAGATG
AATAGGTGTTCTCAGGAGGTAGGGATCTGGCTGAGAGGGAATAATCTGAGCAAAGGTATGAAACAGCCTAATGCATTAGAGAAAAAAGTT
CTTTTAGTAAGGCATTTGGGGTTGGGGAAGCTAGAAAAAGAAATGGGAGCTGGTCACACAGGGCCTTGTGTGCCAGACTAAGGGGTTTGT
AGTATATATTGTAGGCAGAAGAGATCCATCAACAGATTGCAAGCAAGGAAGTATGTTCACTTTAAAGTTTGAGAAAGAATAGTGTGGAAG
CACGTCTCAAATTTAGACTTGTTCCCCCTCTGAACCGTGAATCAGACCATTTCAGGTAGAAGTCTTCCCCGGTTTATCTGATCTACTCGG
GGCCTCAGGCTTCTCAGCTGGGAAGAGAGGATGCAAGACCAGACTGAAGAACACGGTTGAGTCCCCAGAACCAAAAGGGGGCCTTTCTGC
TTCTTAGCCAGCTACCTCTTCGAGTTTTTCAAATTGTGAGGGGGACCATAAAAGGATGGAAACTTTTAGATGACATTCTACAAATTATTT
TTTTCTTTAAATTAAAAGAACCTAGCCAATAAGATAGAGAATGGGCATCTAAGGCATCTCAGAGCTCTCTGATGAAGCCAGGTTGTCAAA
GATCATTTGCAAAAGAAGGGAAAACTGGCATGACAAAAGCTACAGAGAGGAGAGTGAAATATAGAAGTGTTTGAAATGTTCAAGCTCACA
ATAAGCTTAAATTTATAGAAAATGCTAAGGTTGTCAAGAAGGCTTTTTTTTTTTTCTTTTTTAAACCTGAGGGCAAAAAGGAATGGATAA
AGTAGTGTAATGGATTGACAATCAGGAAGAACAGAATAACTCAGTTTTTTTTCTCCTACAAGGAGATATGGCTGGACCAAAATAAAATGA

>In-frame_ENST00000342916_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(amino acids)=340AA_start in transcript=246_stop in transcript=1268
MRPSGTAGAALLALLAALCPASRALEEKKADIAQRYRISKYPTLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLAEITTL
DRSKRNIIGYFEQKDSDNYRVFERVANILHDDCAFLSAFGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWIQDKCVPLVR
EITFENGEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAIDSFRHMYVFGDFK

--------------------------------------------------------------
>In-frame_ENST00000344576_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(transcript)=4701nt_BP=333nt
CCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCC
GGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCACCGCG
CACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGCCGGGG
CAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGCTGACATAGCCCAGAGATACAGGATAA
GCAAATACCCAACCCTCAAATTGTTTCGTAATGGGATGATGATGAAGAGAGAATACAGGGGTCAGCGATCAGTGAAAGCATTGGCAGATT
ACATCAGGCAACAAAAAAGTGACCCCATTCAAGAAATTCGGGACTTAGCAGAAATCACCACTCTTGATCGCAGCAAAAGAAATATCATTG
GATATTTTGAGCAAAAGGACTCGGACAACTATAGAGTTTTTGAACGAGTAGCGAATATTTTGCATGATGACTGTGCCTTTCTTTCTGCAT
TTGGGGATGTTTCAAAACCGGAAAGATATAGTGGCGACAACATAATCTACAAACCACCAGGGCATTCTGCTCCGGATATGGTGTACTTGG
GAGCTATGACAAATTTTGATGTGACTTACAATTGGATTCAAGATAAATGTGTTCCTCTTGTCCGAGAAATAACATTTGAAAATGGAGAGG
AATTGACAGAAGAAGGACTGCCTTTTCTCATACTCTTTCACATGAAAGAAGATACAGAAAGTTTAGAAATATTCCAGAATGAAGTAGCTC
GGCAATTAATAAGTGAAAAAGGTACAATAAACTTTTTACATGCCGATTGTGACAAATTTAGACATCCTCTTCTGCACATACAGAAAACTC
CAGCAGATTGTCCTGTAATCGCTATTGACAGCTTTAGGCATATGTATGTGTTTGGAGACTTCAAAGATGTATTAATTCCTGGAAAACTCA
AGCAATTCGTATTTGACTTACATTCTGGAAAACTGCACAGAGAATTCCATCATGGACCTGACCCAACTGATACAGCCCCAGGAGAGCAAG
CCCAAGATGTAGCAAGCAGTCCACCTGAGAGCTCCTTCCAGAAACTAGCACCCAGTGAATATAGGTATACTCTATTGAGGGATCGAGATG
AGCTTTAAAAACTTGAAAAACAGTTTGTAAGCCTTTCAACAGCAGCATCAACCTACGTGGTGGAAATAGTAAACCTATATTTTCATAATT
CTATGTGTATTTTTATTTTGAATAAACAGAAAGAAATTTTGGGTTTTTAATTTTTTTCTCCCCGACTCAAAATGCATTGTCATTTAATAT
AGTAGCCTCTTAAAAAAAAAAAACCTGCTAGGATTTAAAAATAAAAATCAGAGGCCTATCTCCACTTTAAATCTGTCCTGTAAAAGTTTT
ATAAATCAAATGAAAGGTGACATTGCCAGAAACTTACCATTAACTTGCACTACTAGGGTAGGGAGGACTTAGGGATGTTTCCTGTGTCGT
ATGTGCTTTTCTTTCTTTCATATGATCAATTCTGTTGGTATTTTCAGTATCTCATTTCTCAAAGCTAAAGAGATATACATTCTGGATACT
TGGGAGGGGAATAAATTAAAGTTTTCACACTGTGTACTGTGTTTTACTGATTGGTTGGATATTGCTTATGAAAATTCCATAGTGGTATTT
TTTTGGATTCTTAATGTGTAACTTAAACATACTTTGAAGTGGAGGAGAGTCATAAGACAGAACATTTGGCAGGAATTGTCCTTATGAAAC
AAGAAAAAGAAAATGAAAAGTATTATTAAGCTTCTGTGTTTGTCTAAAAATGTGGCATATGGATGGCATTTAAAACTTTGAATGAATTAT
ACCTAAATCTGGGACAGGGAGGTGACAGTGGAACAGGCTACCAATCAGAACTAGATGACTTTTAAGGCTCCTCCTATTATGAGACTTCAA
TTTCCAAAGAGAAGAACTAGCAGAGAAATTGTATTTCAGTAATTTTAAGCTCCTTCTGTCTTGTAGAGTCTTGTTATAGTTGTATAAATC
AAAAACACAGAATAAGGAACATATTTAACTTTTTTTCATTATAAAATGGTTAGAGGACCCTACCCCCTCTAGATTCCCTGATTTCCCCAG
GCCTGCAGCATACAGTAAGATGGGTCCCTGTGCCAGGCCTCAATACTGCCAGGGAATAAAACCAGAGGGAGAGGACCCTCAGTGTCATAT
CAGGAAGCCCAGTGCCAGAGGACAGACAGGTTCAAAACTGGCTTTTCCTCTGGGCCTGGGTTGGTGCTATAGGCCAAGGGTCATTTTATA
CTTGGGTATAAATCAATCCCAGTTTGGGAAAAGATTATTTTTAAGCTTAAAAGGCTGACATGTGCCATTATATGTAGTATGTAATATATG
TAACATCTTCCAATTCTTTTAAAATAAAATTAATATTTATAATGGATATTTAATGATTGTTATTTTTAAAAACCAGCTTATAATTCCTCG
TTATGCATGATTTATCCAAAGTTTCCATAGTTTTATTCAAAATAATAAATGTTAATAAGGTGATAAGGGGTATATTTAATGTATTGTATC
AAATTGTGAATAAGAAAGTAGGATGGAGCTTTCTAGAGGTTGGGCCTTAGTTCTGTTATCCTCATTGCTTTTAACCAATAAGTTAAATGA
AGTTAGAGTTATGGTCTTCAGGTTAGATTATGGACCAGATCTGTGAGGGTCAGCATGGAAATTCACATTCAACAAGGTAGCACACAGGAC
CAAGAGCAGCACATGCAATCAACTGGAATAATATAGTAATCCTGTAACTGGGTTTGAAAAAATAATCAACAAAAGATACAATTCAAGGGT
TAGGTTGCAGAGAGCTGGCTTGAGAGTAGTTATTATGAAAAAGGCCTCAAGGAGTACGTGTTCAGTATGCTCTAAGATGATAAAGTGGCT
GTTAAAAAGGGAGTTGATTTGAGGAAGTATTACTTAGCATTCATGCATATTGGGCTTAGGCTCTAGCCCTGCCACTATCATTGTCTTCTC
TGGACTGTGAAGTCACTGAGGACAAGGAAACTAAATTTAATGTCTGTATCACTAGTGCCTAGAATTTCTGGACACTTAGTAGTCACCATC
AGGCGTTTATTTAATGAATGAGAAGCAAAGTGACCTTGGTTACTTTTTTACCCTGAGGGGCTCAGCACTCATTAGGACTTGGTGCCTAAT
TTTATAAAAAGTCACTAAGCTCAAGTGCTTGGATGAAAGGACAGCGTGGATAAAAAGGTTTTTAAAACATGGATGTTAAGGCTGTTTTGC
TTGGAGAAGACTTGGGACTGGGACAGTCTTTAGATATTATTTGAAATGCTGGCACTGTCTATCTGGATCCCAGGGCTTGAACTAGGATTT
GAGGAAGTCACAGGGAAGCAGATTTCAGTCTGACATTTATTCAGTGCAAGTTTTTTGGTGCTGTAGTATATGATGAAAGATGTAAAGCTG
AATAAAGCATTATTTCTGCCCTAGAGTTGTTCACAGCCTAGTCAGGCATATGGATATGTAAACAATGACTGTAACGTGTTATAGATGTAA
AGACAAAATAAAGGTTAAAGAGGGCATAAAGGAGCACTCAATTGCAGAGATTTGAGGACATTATTTTTATTTTGAGCTTTAAAAAGATGA
ATAGGTGTTCTCAGGAGGTAGGGATCTGGCTGAGAGGGAATAATCTGAGCAAAGGTATGAAACAGCCTAATGCATTAGAGAAAAAAGTTC
TTTTAGTAAGGCATTTGGGGTTGGGGAAGCTAGAAAAAGAAATGGGAGCTGGTCACACAGGGCCTTGTGTGCCAGACTAAGGGGTTTGTA
GTATATATTGTAGGCAGAAGAGATCCATCAACAGATTGCAAGCAAGGAAGTATGTTCACTTTAAAGTTTGAGAAAGAATAGTGTGGAAGC
ACGTCTCAAATTTAGACTTGTTCCCCCTCTGAACCGTGAATCAGACCATTTCAGGTAGAAGTCTTCCCCGGTTTATCTGATCTACTCGGG
GCCTCAGGCTTCTCAGCTGGGAAGAGAGGATGCAAGACCAGACTGAAGAACACGGTTGAGTCCCCAGAACCAAAAGGGGGCCTTTCTGCT
TCTTAGCCAGCTACCTCTTCGAGTTTTTCAAATTGTGAGGGGGACCATAAAAGGATGGAAACTTTTAGATGACATTCTACAAATTATTTT
TTTCTTTAAATTAAAAGAACCTAGCCAATAAGATAGAGAATGGGCATCTAAGGCATCTCAGAGCTCTCTGATGAAGCCAGGTTGTCAAAG
ATCATTTGCAAAAGAAGGGAAAACTGGCATGACAAAAGCTACAGAGAGGAGAGTGAAATATAGAAGTGTTTGAAATGTTCAAGCTCACAA
TAAGCTTAAATTTATAGAAAATGCTAAGGTTGTCAAGAAGGCTTTTTTTTTTTTCTTTTTTAAACCTGAGGGCAAAAAGGAATGGATAAA
GTAGTGTAATGGATTGACAATCAGGAAGAACAGAATAACTCAGTTTTTTTTCTCCTACAAGGAGATATGGCTGGACCAAAATAAAATGAC

>In-frame_ENST00000344576_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(amino acids)=340AA_start in transcript=245_stop in transcript=1267
MRPSGTAGAALLALLAALCPASRALEEKKADIAQRYRISKYPTLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLAEITTL
DRSKRNIIGYFEQKDSDNYRVFERVANILHDDCAFLSAFGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWIQDKCVPLVR
EITFENGEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAIDSFRHMYVFGDFK

--------------------------------------------------------------
>In-frame_ENST00000420316_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(transcript)=4700nt_BP=332nt
CCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCG
GCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCACCGCGC
ACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGCCGGGGC
AGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGCTGACATAGCCCAGAGATACAGGATAAG
CAAATACCCAACCCTCAAATTGTTTCGTAATGGGATGATGATGAAGAGAGAATACAGGGGTCAGCGATCAGTGAAAGCATTGGCAGATTA
CATCAGGCAACAAAAAAGTGACCCCATTCAAGAAATTCGGGACTTAGCAGAAATCACCACTCTTGATCGCAGCAAAAGAAATATCATTGG
ATATTTTGAGCAAAAGGACTCGGACAACTATAGAGTTTTTGAACGAGTAGCGAATATTTTGCATGATGACTGTGCCTTTCTTTCTGCATT
TGGGGATGTTTCAAAACCGGAAAGATATAGTGGCGACAACATAATCTACAAACCACCAGGGCATTCTGCTCCGGATATGGTGTACTTGGG
AGCTATGACAAATTTTGATGTGACTTACAATTGGATTCAAGATAAATGTGTTCCTCTTGTCCGAGAAATAACATTTGAAAATGGAGAGGA
ATTGACAGAAGAAGGACTGCCTTTTCTCATACTCTTTCACATGAAAGAAGATACAGAAAGTTTAGAAATATTCCAGAATGAAGTAGCTCG
GCAATTAATAAGTGAAAAAGGTACAATAAACTTTTTACATGCCGATTGTGACAAATTTAGACATCCTCTTCTGCACATACAGAAAACTCC
AGCAGATTGTCCTGTAATCGCTATTGACAGCTTTAGGCATATGTATGTGTTTGGAGACTTCAAAGATGTATTAATTCCTGGAAAACTCAA
GCAATTCGTATTTGACTTACATTCTGGAAAACTGCACAGAGAATTCCATCATGGACCTGACCCAACTGATACAGCCCCAGGAGAGCAAGC
CCAAGATGTAGCAAGCAGTCCACCTGAGAGCTCCTTCCAGAAACTAGCACCCAGTGAATATAGGTATACTCTATTGAGGGATCGAGATGA
GCTTTAAAAACTTGAAAAACAGTTTGTAAGCCTTTCAACAGCAGCATCAACCTACGTGGTGGAAATAGTAAACCTATATTTTCATAATTC
TATGTGTATTTTTATTTTGAATAAACAGAAAGAAATTTTGGGTTTTTAATTTTTTTCTCCCCGACTCAAAATGCATTGTCATTTAATATA
GTAGCCTCTTAAAAAAAAAAAACCTGCTAGGATTTAAAAATAAAAATCAGAGGCCTATCTCCACTTTAAATCTGTCCTGTAAAAGTTTTA
TAAATCAAATGAAAGGTGACATTGCCAGAAACTTACCATTAACTTGCACTACTAGGGTAGGGAGGACTTAGGGATGTTTCCTGTGTCGTA
TGTGCTTTTCTTTCTTTCATATGATCAATTCTGTTGGTATTTTCAGTATCTCATTTCTCAAAGCTAAAGAGATATACATTCTGGATACTT
GGGAGGGGAATAAATTAAAGTTTTCACACTGTGTACTGTGTTTTACTGATTGGTTGGATATTGCTTATGAAAATTCCATAGTGGTATTTT
TTTGGATTCTTAATGTGTAACTTAAACATACTTTGAAGTGGAGGAGAGTCATAAGACAGAACATTTGGCAGGAATTGTCCTTATGAAACA
AGAAAAAGAAAATGAAAAGTATTATTAAGCTTCTGTGTTTGTCTAAAAATGTGGCATATGGATGGCATTTAAAACTTTGAATGAATTATA
CCTAAATCTGGGACAGGGAGGTGACAGTGGAACAGGCTACCAATCAGAACTAGATGACTTTTAAGGCTCCTCCTATTATGAGACTTCAAT
TTCCAAAGAGAAGAACTAGCAGAGAAATTGTATTTCAGTAATTTTAAGCTCCTTCTGTCTTGTAGAGTCTTGTTATAGTTGTATAAATCA
AAAACACAGAATAAGGAACATATTTAACTTTTTTTCATTATAAAATGGTTAGAGGACCCTACCCCCTCTAGATTCCCTGATTTCCCCAGG
CCTGCAGCATACAGTAAGATGGGTCCCTGTGCCAGGCCTCAATACTGCCAGGGAATAAAACCAGAGGGAGAGGACCCTCAGTGTCATATC
AGGAAGCCCAGTGCCAGAGGACAGACAGGTTCAAAACTGGCTTTTCCTCTGGGCCTGGGTTGGTGCTATAGGCCAAGGGTCATTTTATAC
TTGGGTATAAATCAATCCCAGTTTGGGAAAAGATTATTTTTAAGCTTAAAAGGCTGACATGTGCCATTATATGTAGTATGTAATATATGT
AACATCTTCCAATTCTTTTAAAATAAAATTAATATTTATAATGGATATTTAATGATTGTTATTTTTAAAAACCAGCTTATAATTCCTCGT
TATGCATGATTTATCCAAAGTTTCCATAGTTTTATTCAAAATAATAAATGTTAATAAGGTGATAAGGGGTATATTTAATGTATTGTATCA
AATTGTGAATAAGAAAGTAGGATGGAGCTTTCTAGAGGTTGGGCCTTAGTTCTGTTATCCTCATTGCTTTTAACCAATAAGTTAAATGAA
GTTAGAGTTATGGTCTTCAGGTTAGATTATGGACCAGATCTGTGAGGGTCAGCATGGAAATTCACATTCAACAAGGTAGCACACAGGACC
AAGAGCAGCACATGCAATCAACTGGAATAATATAGTAATCCTGTAACTGGGTTTGAAAAAATAATCAACAAAAGATACAATTCAAGGGTT
AGGTTGCAGAGAGCTGGCTTGAGAGTAGTTATTATGAAAAAGGCCTCAAGGAGTACGTGTTCAGTATGCTCTAAGATGATAAAGTGGCTG
TTAAAAAGGGAGTTGATTTGAGGAAGTATTACTTAGCATTCATGCATATTGGGCTTAGGCTCTAGCCCTGCCACTATCATTGTCTTCTCT
GGACTGTGAAGTCACTGAGGACAAGGAAACTAAATTTAATGTCTGTATCACTAGTGCCTAGAATTTCTGGACACTTAGTAGTCACCATCA
GGCGTTTATTTAATGAATGAGAAGCAAAGTGACCTTGGTTACTTTTTTACCCTGAGGGGCTCAGCACTCATTAGGACTTGGTGCCTAATT
TTATAAAAAGTCACTAAGCTCAAGTGCTTGGATGAAAGGACAGCGTGGATAAAAAGGTTTTTAAAACATGGATGTTAAGGCTGTTTTGCT
TGGAGAAGACTTGGGACTGGGACAGTCTTTAGATATTATTTGAAATGCTGGCACTGTCTATCTGGATCCCAGGGCTTGAACTAGGATTTG
AGGAAGTCACAGGGAAGCAGATTTCAGTCTGACATTTATTCAGTGCAAGTTTTTTGGTGCTGTAGTATATGATGAAAGATGTAAAGCTGA
ATAAAGCATTATTTCTGCCCTAGAGTTGTTCACAGCCTAGTCAGGCATATGGATATGTAAACAATGACTGTAACGTGTTATAGATGTAAA
GACAAAATAAAGGTTAAAGAGGGCATAAAGGAGCACTCAATTGCAGAGATTTGAGGACATTATTTTTATTTTGAGCTTTAAAAAGATGAA
TAGGTGTTCTCAGGAGGTAGGGATCTGGCTGAGAGGGAATAATCTGAGCAAAGGTATGAAACAGCCTAATGCATTAGAGAAAAAAGTTCT
TTTAGTAAGGCATTTGGGGTTGGGGAAGCTAGAAAAAGAAATGGGAGCTGGTCACACAGGGCCTTGTGTGCCAGACTAAGGGGTTTGTAG
TATATATTGTAGGCAGAAGAGATCCATCAACAGATTGCAAGCAAGGAAGTATGTTCACTTTAAAGTTTGAGAAAGAATAGTGTGGAAGCA
CGTCTCAAATTTAGACTTGTTCCCCCTCTGAACCGTGAATCAGACCATTTCAGGTAGAAGTCTTCCCCGGTTTATCTGATCTACTCGGGG
CCTCAGGCTTCTCAGCTGGGAAGAGAGGATGCAAGACCAGACTGAAGAACACGGTTGAGTCCCCAGAACCAAAAGGGGGCCTTTCTGCTT
CTTAGCCAGCTACCTCTTCGAGTTTTTCAAATTGTGAGGGGGACCATAAAAGGATGGAAACTTTTAGATGACATTCTACAAATTATTTTT
TTCTTTAAATTAAAAGAACCTAGCCAATAAGATAGAGAATGGGCATCTAAGGCATCTCAGAGCTCTCTGATGAAGCCAGGTTGTCAAAGA
TCATTTGCAAAAGAAGGGAAAACTGGCATGACAAAAGCTACAGAGAGGAGAGTGAAATATAGAAGTGTTTGAAATGTTCAAGCTCACAAT
AAGCTTAAATTTATAGAAAATGCTAAGGTTGTCAAGAAGGCTTTTTTTTTTTTCTTTTTTAAACCTGAGGGCAAAAAGGAATGGATAAAG
TAGTGTAATGGATTGACAATCAGGAAGAACAGAATAACTCAGTTTTTTTTCTCCTACAAGGAGATATGGCTGGACCAAAATAAAATGACA

>In-frame_ENST00000420316_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(amino acids)=340AA_start in transcript=244_stop in transcript=1266
MRPSGTAGAALLALLAALCPASRALEEKKADIAQRYRISKYPTLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLAEITTL
DRSKRNIIGYFEQKDSDNYRVFERVANILHDDCAFLSAFGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWIQDKCVPLVR
EITFENGEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAIDSFRHMYVFGDFK

--------------------------------------------------------------
>In-frame_ENST00000275493_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(transcript)=4633nt_BP=265nt
GCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGC
CGCCAACGCCACAACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATG
CGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGCTGAC
ATAGCCCAGAGATACAGGATAAGCAAATACCCAACCCTCAAATTGTTTCGTAATGGGATGATGATGAAGAGAGAATACAGGGGTCAGCGA
TCAGTGAAAGCATTGGCAGATTACATCAGGCAACAAAAAAGTGACCCCATTCAAGAAATTCGGGACTTAGCAGAAATCACCACTCTTGAT
CGCAGCAAAAGAAATATCATTGGATATTTTGAGCAAAAGGACTCGGACAACTATAGAGTTTTTGAACGAGTAGCGAATATTTTGCATGAT
GACTGTGCCTTTCTTTCTGCATTTGGGGATGTTTCAAAACCGGAAAGATATAGTGGCGACAACATAATCTACAAACCACCAGGGCATTCT
GCTCCGGATATGGTGTACTTGGGAGCTATGACAAATTTTGATGTGACTTACAATTGGATTCAAGATAAATGTGTTCCTCTTGTCCGAGAA
ATAACATTTGAAAATGGAGAGGAATTGACAGAAGAAGGACTGCCTTTTCTCATACTCTTTCACATGAAAGAAGATACAGAAAGTTTAGAA
ATATTCCAGAATGAAGTAGCTCGGCAATTAATAAGTGAAAAAGGTACAATAAACTTTTTACATGCCGATTGTGACAAATTTAGACATCCT
CTTCTGCACATACAGAAAACTCCAGCAGATTGTCCTGTAATCGCTATTGACAGCTTTAGGCATATGTATGTGTTTGGAGACTTCAAAGAT
GTATTAATTCCTGGAAAACTCAAGCAATTCGTATTTGACTTACATTCTGGAAAACTGCACAGAGAATTCCATCATGGACCTGACCCAACT
GATACAGCCCCAGGAGAGCAAGCCCAAGATGTAGCAAGCAGTCCACCTGAGAGCTCCTTCCAGAAACTAGCACCCAGTGAATATAGGTAT
ACTCTATTGAGGGATCGAGATGAGCTTTAAAAACTTGAAAAACAGTTTGTAAGCCTTTCAACAGCAGCATCAACCTACGTGGTGGAAATA
GTAAACCTATATTTTCATAATTCTATGTGTATTTTTATTTTGAATAAACAGAAAGAAATTTTGGGTTTTTAATTTTTTTCTCCCCGACTC
AAAATGCATTGTCATTTAATATAGTAGCCTCTTAAAAAAAAAAAACCTGCTAGGATTTAAAAATAAAAATCAGAGGCCTATCTCCACTTT
AAATCTGTCCTGTAAAAGTTTTATAAATCAAATGAAAGGTGACATTGCCAGAAACTTACCATTAACTTGCACTACTAGGGTAGGGAGGAC
TTAGGGATGTTTCCTGTGTCGTATGTGCTTTTCTTTCTTTCATATGATCAATTCTGTTGGTATTTTCAGTATCTCATTTCTCAAAGCTAA
AGAGATATACATTCTGGATACTTGGGAGGGGAATAAATTAAAGTTTTCACACTGTGTACTGTGTTTTACTGATTGGTTGGATATTGCTTA
TGAAAATTCCATAGTGGTATTTTTTTGGATTCTTAATGTGTAACTTAAACATACTTTGAAGTGGAGGAGAGTCATAAGACAGAACATTTG
GCAGGAATTGTCCTTATGAAACAAGAAAAAGAAAATGAAAAGTATTATTAAGCTTCTGTGTTTGTCTAAAAATGTGGCATATGGATGGCA
TTTAAAACTTTGAATGAATTATACCTAAATCTGGGACAGGGAGGTGACAGTGGAACAGGCTACCAATCAGAACTAGATGACTTTTAAGGC
TCCTCCTATTATGAGACTTCAATTTCCAAAGAGAAGAACTAGCAGAGAAATTGTATTTCAGTAATTTTAAGCTCCTTCTGTCTTGTAGAG
TCTTGTTATAGTTGTATAAATCAAAAACACAGAATAAGGAACATATTTAACTTTTTTTCATTATAAAATGGTTAGAGGACCCTACCCCCT
CTAGATTCCCTGATTTCCCCAGGCCTGCAGCATACAGTAAGATGGGTCCCTGTGCCAGGCCTCAATACTGCCAGGGAATAAAACCAGAGG
GAGAGGACCCTCAGTGTCATATCAGGAAGCCCAGTGCCAGAGGACAGACAGGTTCAAAACTGGCTTTTCCTCTGGGCCTGGGTTGGTGCT
ATAGGCCAAGGGTCATTTTATACTTGGGTATAAATCAATCCCAGTTTGGGAAAAGATTATTTTTAAGCTTAAAAGGCTGACATGTGCCAT
TATATGTAGTATGTAATATATGTAACATCTTCCAATTCTTTTAAAATAAAATTAATATTTATAATGGATATTTAATGATTGTTATTTTTA
AAAACCAGCTTATAATTCCTCGTTATGCATGATTTATCCAAAGTTTCCATAGTTTTATTCAAAATAATAAATGTTAATAAGGTGATAAGG
GGTATATTTAATGTATTGTATCAAATTGTGAATAAGAAAGTAGGATGGAGCTTTCTAGAGGTTGGGCCTTAGTTCTGTTATCCTCATTGC
TTTTAACCAATAAGTTAAATGAAGTTAGAGTTATGGTCTTCAGGTTAGATTATGGACCAGATCTGTGAGGGTCAGCATGGAAATTCACAT
TCAACAAGGTAGCACACAGGACCAAGAGCAGCACATGCAATCAACTGGAATAATATAGTAATCCTGTAACTGGGTTTGAAAAAATAATCA
ACAAAAGATACAATTCAAGGGTTAGGTTGCAGAGAGCTGGCTTGAGAGTAGTTATTATGAAAAAGGCCTCAAGGAGTACGTGTTCAGTAT
GCTCTAAGATGATAAAGTGGCTGTTAAAAAGGGAGTTGATTTGAGGAAGTATTACTTAGCATTCATGCATATTGGGCTTAGGCTCTAGCC
CTGCCACTATCATTGTCTTCTCTGGACTGTGAAGTCACTGAGGACAAGGAAACTAAATTTAATGTCTGTATCACTAGTGCCTAGAATTTC
TGGACACTTAGTAGTCACCATCAGGCGTTTATTTAATGAATGAGAAGCAAAGTGACCTTGGTTACTTTTTTACCCTGAGGGGCTCAGCAC
TCATTAGGACTTGGTGCCTAATTTTATAAAAAGTCACTAAGCTCAAGTGCTTGGATGAAAGGACAGCGTGGATAAAAAGGTTTTTAAAAC
ATGGATGTTAAGGCTGTTTTGCTTGGAGAAGACTTGGGACTGGGACAGTCTTTAGATATTATTTGAAATGCTGGCACTGTCTATCTGGAT
CCCAGGGCTTGAACTAGGATTTGAGGAAGTCACAGGGAAGCAGATTTCAGTCTGACATTTATTCAGTGCAAGTTTTTTGGTGCTGTAGTA
TATGATGAAAGATGTAAAGCTGAATAAAGCATTATTTCTGCCCTAGAGTTGTTCACAGCCTAGTCAGGCATATGGATATGTAAACAATGA
CTGTAACGTGTTATAGATGTAAAGACAAAATAAAGGTTAAAGAGGGCATAAAGGAGCACTCAATTGCAGAGATTTGAGGACATTATTTTT
ATTTTGAGCTTTAAAAAGATGAATAGGTGTTCTCAGGAGGTAGGGATCTGGCTGAGAGGGAATAATCTGAGCAAAGGTATGAAACAGCCT
AATGCATTAGAGAAAAAAGTTCTTTTAGTAAGGCATTTGGGGTTGGGGAAGCTAGAAAAAGAAATGGGAGCTGGTCACACAGGGCCTTGT
GTGCCAGACTAAGGGGTTTGTAGTATATATTGTAGGCAGAAGAGATCCATCAACAGATTGCAAGCAAGGAAGTATGTTCACTTTAAAGTT
TGAGAAAGAATAGTGTGGAAGCACGTCTCAAATTTAGACTTGTTCCCCCTCTGAACCGTGAATCAGACCATTTCAGGTAGAAGTCTTCCC
CGGTTTATCTGATCTACTCGGGGCCTCAGGCTTCTCAGCTGGGAAGAGAGGATGCAAGACCAGACTGAAGAACACGGTTGAGTCCCCAGA
ACCAAAAGGGGGCCTTTCTGCTTCTTAGCCAGCTACCTCTTCGAGTTTTTCAAATTGTGAGGGGGACCATAAAAGGATGGAAACTTTTAG
ATGACATTCTACAAATTATTTTTTTCTTTAAATTAAAAGAACCTAGCCAATAAGATAGAGAATGGGCATCTAAGGCATCTCAGAGCTCTC
TGATGAAGCCAGGTTGTCAAAGATCATTTGCAAAAGAAGGGAAAACTGGCATGACAAAAGCTACAGAGAGGAGAGTGAAATATAGAAGTG
TTTGAAATGTTCAAGCTCACAATAAGCTTAAATTTATAGAAAATGCTAAGGTTGTCAAGAAGGCTTTTTTTTTTTTCTTTTTTAAACCTG
AGGGCAAAAAGGAATGGATAAAGTAGTGTAATGGATTGACAATCAGGAAGAACAGAATAACTCAGTTTTTTTTCTCCTACAAGGAGATAT

>In-frame_ENST00000275493_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(amino acids)=340AA_start in transcript=177_stop in transcript=1199
MRPSGTAGAALLALLAALCPASRALEEKKADIAQRYRISKYPTLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLAEITTL
DRSKRNIIGYFEQKDSDNYRVFERVANILHDDCAFLSAFGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWIQDKCVPLVR
EITFENGEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAIDSFRHMYVFGDFK

--------------------------------------------------------------
>In-frame_ENST00000442591_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(transcript)=4616nt_BP=248nt
GCCCCGGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCA
CCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGC
CGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGCTGACATAGCCCAGAGATACAG
GATAAGCAAATACCCAACCCTCAAATTGTTTCGTAATGGGATGATGATGAAGAGAGAATACAGGGGTCAGCGATCAGTGAAAGCATTGGC
AGATTACATCAGGCAACAAAAAAGTGACCCCATTCAAGAAATTCGGGACTTAGCAGAAATCACCACTCTTGATCGCAGCAAAAGAAATAT
CATTGGATATTTTGAGCAAAAGGACTCGGACAACTATAGAGTTTTTGAACGAGTAGCGAATATTTTGCATGATGACTGTGCCTTTCTTTC
TGCATTTGGGGATGTTTCAAAACCGGAAAGATATAGTGGCGACAACATAATCTACAAACCACCAGGGCATTCTGCTCCGGATATGGTGTA
CTTGGGAGCTATGACAAATTTTGATGTGACTTACAATTGGATTCAAGATAAATGTGTTCCTCTTGTCCGAGAAATAACATTTGAAAATGG
AGAGGAATTGACAGAAGAAGGACTGCCTTTTCTCATACTCTTTCACATGAAAGAAGATACAGAAAGTTTAGAAATATTCCAGAATGAAGT
AGCTCGGCAATTAATAAGTGAAAAAGGTACAATAAACTTTTTACATGCCGATTGTGACAAATTTAGACATCCTCTTCTGCACATACAGAA
AACTCCAGCAGATTGTCCTGTAATCGCTATTGACAGCTTTAGGCATATGTATGTGTTTGGAGACTTCAAAGATGTATTAATTCCTGGAAA
ACTCAAGCAATTCGTATTTGACTTACATTCTGGAAAACTGCACAGAGAATTCCATCATGGACCTGACCCAACTGATACAGCCCCAGGAGA
GCAAGCCCAAGATGTAGCAAGCAGTCCACCTGAGAGCTCCTTCCAGAAACTAGCACCCAGTGAATATAGGTATACTCTATTGAGGGATCG
AGATGAGCTTTAAAAACTTGAAAAACAGTTTGTAAGCCTTTCAACAGCAGCATCAACCTACGTGGTGGAAATAGTAAACCTATATTTTCA
TAATTCTATGTGTATTTTTATTTTGAATAAACAGAAAGAAATTTTGGGTTTTTAATTTTTTTCTCCCCGACTCAAAATGCATTGTCATTT
AATATAGTAGCCTCTTAAAAAAAAAAAACCTGCTAGGATTTAAAAATAAAAATCAGAGGCCTATCTCCACTTTAAATCTGTCCTGTAAAA
GTTTTATAAATCAAATGAAAGGTGACATTGCCAGAAACTTACCATTAACTTGCACTACTAGGGTAGGGAGGACTTAGGGATGTTTCCTGT
GTCGTATGTGCTTTTCTTTCTTTCATATGATCAATTCTGTTGGTATTTTCAGTATCTCATTTCTCAAAGCTAAAGAGATATACATTCTGG
ATACTTGGGAGGGGAATAAATTAAAGTTTTCACACTGTGTACTGTGTTTTACTGATTGGTTGGATATTGCTTATGAAAATTCCATAGTGG
TATTTTTTTGGATTCTTAATGTGTAACTTAAACATACTTTGAAGTGGAGGAGAGTCATAAGACAGAACATTTGGCAGGAATTGTCCTTAT
GAAACAAGAAAAAGAAAATGAAAAGTATTATTAAGCTTCTGTGTTTGTCTAAAAATGTGGCATATGGATGGCATTTAAAACTTTGAATGA
ATTATACCTAAATCTGGGACAGGGAGGTGACAGTGGAACAGGCTACCAATCAGAACTAGATGACTTTTAAGGCTCCTCCTATTATGAGAC
TTCAATTTCCAAAGAGAAGAACTAGCAGAGAAATTGTATTTCAGTAATTTTAAGCTCCTTCTGTCTTGTAGAGTCTTGTTATAGTTGTAT
AAATCAAAAACACAGAATAAGGAACATATTTAACTTTTTTTCATTATAAAATGGTTAGAGGACCCTACCCCCTCTAGATTCCCTGATTTC
CCCAGGCCTGCAGCATACAGTAAGATGGGTCCCTGTGCCAGGCCTCAATACTGCCAGGGAATAAAACCAGAGGGAGAGGACCCTCAGTGT
CATATCAGGAAGCCCAGTGCCAGAGGACAGACAGGTTCAAAACTGGCTTTTCCTCTGGGCCTGGGTTGGTGCTATAGGCCAAGGGTCATT
TTATACTTGGGTATAAATCAATCCCAGTTTGGGAAAAGATTATTTTTAAGCTTAAAAGGCTGACATGTGCCATTATATGTAGTATGTAAT
ATATGTAACATCTTCCAATTCTTTTAAAATAAAATTAATATTTATAATGGATATTTAATGATTGTTATTTTTAAAAACCAGCTTATAATT
CCTCGTTATGCATGATTTATCCAAAGTTTCCATAGTTTTATTCAAAATAATAAATGTTAATAAGGTGATAAGGGGTATATTTAATGTATT
GTATCAAATTGTGAATAAGAAAGTAGGATGGAGCTTTCTAGAGGTTGGGCCTTAGTTCTGTTATCCTCATTGCTTTTAACCAATAAGTTA
AATGAAGTTAGAGTTATGGTCTTCAGGTTAGATTATGGACCAGATCTGTGAGGGTCAGCATGGAAATTCACATTCAACAAGGTAGCACAC
AGGACCAAGAGCAGCACATGCAATCAACTGGAATAATATAGTAATCCTGTAACTGGGTTTGAAAAAATAATCAACAAAAGATACAATTCA
AGGGTTAGGTTGCAGAGAGCTGGCTTGAGAGTAGTTATTATGAAAAAGGCCTCAAGGAGTACGTGTTCAGTATGCTCTAAGATGATAAAG
TGGCTGTTAAAAAGGGAGTTGATTTGAGGAAGTATTACTTAGCATTCATGCATATTGGGCTTAGGCTCTAGCCCTGCCACTATCATTGTC
TTCTCTGGACTGTGAAGTCACTGAGGACAAGGAAACTAAATTTAATGTCTGTATCACTAGTGCCTAGAATTTCTGGACACTTAGTAGTCA
CCATCAGGCGTTTATTTAATGAATGAGAAGCAAAGTGACCTTGGTTACTTTTTTACCCTGAGGGGCTCAGCACTCATTAGGACTTGGTGC
CTAATTTTATAAAAAGTCACTAAGCTCAAGTGCTTGGATGAAAGGACAGCGTGGATAAAAAGGTTTTTAAAACATGGATGTTAAGGCTGT
TTTGCTTGGAGAAGACTTGGGACTGGGACAGTCTTTAGATATTATTTGAAATGCTGGCACTGTCTATCTGGATCCCAGGGCTTGAACTAG
GATTTGAGGAAGTCACAGGGAAGCAGATTTCAGTCTGACATTTATTCAGTGCAAGTTTTTTGGTGCTGTAGTATATGATGAAAGATGTAA
AGCTGAATAAAGCATTATTTCTGCCCTAGAGTTGTTCACAGCCTAGTCAGGCATATGGATATGTAAACAATGACTGTAACGTGTTATAGA
TGTAAAGACAAAATAAAGGTTAAAGAGGGCATAAAGGAGCACTCAATTGCAGAGATTTGAGGACATTATTTTTATTTTGAGCTTTAAAAA
GATGAATAGGTGTTCTCAGGAGGTAGGGATCTGGCTGAGAGGGAATAATCTGAGCAAAGGTATGAAACAGCCTAATGCATTAGAGAAAAA
AGTTCTTTTAGTAAGGCATTTGGGGTTGGGGAAGCTAGAAAAAGAAATGGGAGCTGGTCACACAGGGCCTTGTGTGCCAGACTAAGGGGT
TTGTAGTATATATTGTAGGCAGAAGAGATCCATCAACAGATTGCAAGCAAGGAAGTATGTTCACTTTAAAGTTTGAGAAAGAATAGTGTG
GAAGCACGTCTCAAATTTAGACTTGTTCCCCCTCTGAACCGTGAATCAGACCATTTCAGGTAGAAGTCTTCCCCGGTTTATCTGATCTAC
TCGGGGCCTCAGGCTTCTCAGCTGGGAAGAGAGGATGCAAGACCAGACTGAAGAACACGGTTGAGTCCCCAGAACCAAAAGGGGGCCTTT
CTGCTTCTTAGCCAGCTACCTCTTCGAGTTTTTCAAATTGTGAGGGGGACCATAAAAGGATGGAAACTTTTAGATGACATTCTACAAATT
ATTTTTTTCTTTAAATTAAAAGAACCTAGCCAATAAGATAGAGAATGGGCATCTAAGGCATCTCAGAGCTCTCTGATGAAGCCAGGTTGT
CAAAGATCATTTGCAAAAGAAGGGAAAACTGGCATGACAAAAGCTACAGAGAGGAGAGTGAAATATAGAAGTGTTTGAAATGTTCAAGCT
CACAATAAGCTTAAATTTATAGAAAATGCTAAGGTTGTCAAGAAGGCTTTTTTTTTTTTCTTTTTTAAACCTGAGGGCAAAAAGGAATGG
ATAAAGTAGTGTAATGGATTGACAATCAGGAAGAACAGAATAACTCAGTTTTTTTTCTCCTACAAGGAGATATGGCTGGACCAAAATAAA

>In-frame_ENST00000442591_ENST00000262455_TCGA-06-0744_EGFR_chr7_55087058_+_ERP44_chr9_102784508_length(amino acids)=340AA_start in transcript=160_stop in transcript=1182
MRPSGTAGAALLALLAALCPASRALEEKKADIAQRYRISKYPTLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLAEITTL
DRSKRNIIGYFEQKDSDNYRVFERVANILHDDCAFLSAFGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWIQDKCVPLVR
EITFENGEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAIDSFRHMYVFGDFK

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for EGFR-ERP44


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with
TgeneERP44chr7:55087058chr9:102784508ENST00000262455312236_28595.33333333333333407.0ITPR1


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for EGFR-ERP44


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
HgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
HgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
HgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
HgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
HgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
HgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
HgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
HgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
HgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
HgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
HgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
HgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
HgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
HgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
HgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
HgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
HgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
HgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
HgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
HgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
HgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
HgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
HgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved

Top

Related Diseases for EGFR-ERP44


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneEGFRC0007131Non-Small Cell Lung Carcinoma16CGI;CTD_human
HgeneEGFRC0024121Lung Neoplasms7CGI;CTD_human
HgeneEGFRC0242379Malignant neoplasm of lung7CGI;CTD_human
HgeneEGFRC0006142Malignant neoplasm of breast6CTD_human
HgeneEGFRC0678222Breast Carcinoma6CTD_human
HgeneEGFRC1257931Mammary Neoplasms, Human6CTD_human
HgeneEGFRC1458155Mammary Neoplasms6CTD_human
HgeneEGFRC4704874Mammary Carcinoma, Human6CTD_human
HgeneEGFRC0001418Adenocarcinoma5CTD_human
HgeneEGFRC0205641Adenocarcinoma, Basal Cell5CTD_human
HgeneEGFRC0205642Adenocarcinoma, Oxyphilic5CTD_human
HgeneEGFRC0205643Carcinoma, Cribriform5CTD_human
HgeneEGFRC0205644Carcinoma, Granular Cell5CTD_human
HgeneEGFRC0205645Adenocarcinoma, Tubular5CTD_human
HgeneEGFRC0334588Giant Cell Glioblastoma5CTD_human;ORPHANET
HgeneEGFRC0007137Squamous cell carcinoma3CTD_human
HgeneEGFRC0007873Uterine Cervical Neoplasm3CTD_human
HgeneEGFRC0014859Esophageal Neoplasms3CGI;CTD_human
HgeneEGFRC0017636Glioblastoma3CGI;CTD_human
HgeneEGFRC0018671Head and Neck Neoplasms3CGI;CTD_human
HgeneEGFRC0018675Head Neoplasms3CTD_human
HgeneEGFRC0024623Malignant neoplasm of stomach3CTD_human
HgeneEGFRC0027533Neck Neoplasms3CTD_human
HgeneEGFRC0027627Neoplasm Metastasis3CTD_human
HgeneEGFRC0033578Prostatic Neoplasms3CTD_human
HgeneEGFRC0038356Stomach Neoplasms3CTD_human
HgeneEGFRC0278996Malignant Head and Neck Neoplasm3CGI;CTD_human
HgeneEGFRC0376358Malignant neoplasm of prostate3CTD_human
HgeneEGFRC0546837Malignant neoplasm of esophagus3CGI;CTD_human
HgeneEGFRC0746787Cancer of Neck3CTD_human
HgeneEGFRC0751177Cancer of Head3CTD_human
HgeneEGFRC0887900Upper Aerodigestive Tract Neoplasms3CTD_human
HgeneEGFRC1621958Glioblastoma Multiforme3CTD_human
HgeneEGFRC1708349Hereditary Diffuse Gastric Cancer3CTD_human
HgeneEGFRC4048328cervical cancer3CTD_human
HgeneEGFRC0005684Malignant neoplasm of urinary bladder2CTD_human
HgeneEGFRC0005695Bladder Neoplasm2CTD_human
HgeneEGFRC0007102Malignant tumor of colon2CTD_human
HgeneEGFRC0009375Colonic Neoplasms2CTD_human
HgeneEGFRC0009402Colorectal Carcinoma2CTD_human
HgeneEGFRC0009404Colorectal Neoplasms2CTD_human
HgeneEGFRC0024668Mammary Neoplasms, Experimental2CTD_human
HgeneEGFRC0027626Neoplasm Invasiveness2CTD_human
HgeneEGFRC0027643Neoplasm Recurrence, Local2CTD_human
HgeneEGFRC0152013Adenocarcinoma of lung (disorder)2CGI;CTD_human
HgeneEGFRC0206726gliosarcoma2ORPHANET
HgeneEGFRC0919267ovarian neoplasm2CTD_human
HgeneEGFRC1140680Malignant neoplasm of ovary2CTD_human
HgeneEGFRC4015130INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 22CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneEGFRC0001973Alcoholic Intoxication, Chronic1PSYGENET
HgeneEGFRC0003865Arthritis, Adjuvant-Induced1CTD_human
HgeneEGFRC0005396Bile Duct Neoplasms1CTD_human
HgeneEGFRC0007097Carcinoma1CTD_human
HgeneEGFRC0007113Rectal Carcinoma1CTD_human
HgeneEGFRC0007193Cardiomyopathy, Dilated1CTD_human
HgeneEGFRC0011603Dermatitis1CTD_human
HgeneEGFRC0011860Diabetes Mellitus, Non-Insulin-Dependent1CTD_human
HgeneEGFRC0014175Endometriosis1CTD_human
HgeneEGFRC0016978gallbladder neoplasm1CTD_human
HgeneEGFRC0021655Insulin Resistance1CTD_human
HgeneEGFRC0022660Kidney Failure, Acute1CTD_human
HgeneEGFRC0024667Animal Mammary Neoplasms1CTD_human
HgeneEGFRC0024809Marijuana Abuse1PSYGENET
HgeneEGFRC0025500Mesothelioma1CTD_human
HgeneEGFRC0027439Nasopharyngeal Neoplasms1CTD_human
HgeneEGFRC0029463Osteosarcoma1CTD_human
HgeneEGFRC0030297Pancreatic Neoplasm1CTD_human
HgeneEGFRC0030354Papilloma1CTD_human
HgeneEGFRC0032580Adenomatous Polyposis Coli1CTD_human
HgeneEGFRC0034885Rectal Neoplasms1CTD_human
HgeneEGFRC0041696Unipolar Depression1PSYGENET
HgeneEGFRC0085548Autosomal Recessive Polycystic Kidney Disease1CTD_human
HgeneEGFRC0085762Alcohol abuse1PSYGENET
HgeneEGFRC0149925Small cell carcinoma of lung1CTD_human
HgeneEGFRC0153452Malignant neoplasm of gallbladder1CTD_human
HgeneEGFRC0205696Anaplastic carcinoma1CTD_human
HgeneEGFRC0205697Carcinoma, Spindle-Cell1CTD_human
HgeneEGFRC0205698Undifferentiated carcinoma1CTD_human
HgeneEGFRC0205699Carcinomatosis1CTD_human
HgeneEGFRC0205874Papilloma, Squamous Cell1CTD_human
HgeneEGFRC0205875Papillomatosis1CTD_human
HgeneEGFRC0206686Adrenocortical carcinoma1CTD_human
HgeneEGFRC0206698Cholangiocarcinoma1CTD_human
HgeneEGFRC0235874Disease Exacerbation1CTD_human
HgeneEGFRC0238301Cancer of Nasopharynx1CTD_human
HgeneEGFRC0263454Chloracne1CTD_human
HgeneEGFRC0269102Endometrioma1CTD_human
HgeneEGFRC0279626Squamous cell carcinoma of esophagus1CGI;CTD_human
HgeneEGFRC0345905Intrahepatic Cholangiocarcinoma1CTD_human
HgeneEGFRC0345967Malignant mesothelioma1CTD_human
HgeneEGFRC0346647Malignant neoplasm of pancreas1CTD_human
HgeneEGFRC0376634Craniofacial Abnormalities1CTD_human
HgeneEGFRC0740277Bile duct carcinoma1CTD_human
HgeneEGFRC0920563Insulin Sensitivity1CTD_human
HgeneEGFRC0971858Arthritis, Collagen-Induced1CTD_human
HgeneEGFRC0993582Arthritis, Experimental1CTD_human
HgeneEGFRC1257925Mammary Carcinoma, Animal1CTD_human
HgeneEGFRC1269683Major Depressive Disorder1PSYGENET
HgeneEGFRC1449563Cardiomyopathy, Familial Idiopathic1CTD_human
HgeneEGFRC1565662Acute Kidney Insufficiency1CTD_human
HgeneEGFRC2239176Liver carcinoma1CTD_human
HgeneEGFRC2609414Acute kidney injury1CTD_human
HgeneEGFRC2713442Polyposis, Adenomatous Intestinal1CTD_human
HgeneEGFRC2713443Familial Intestinal Polyposis1CTD_human
HgeneEGFRC3805278Extrahepatic Cholangiocarcinoma1CTD_human
HgeneEGFRC4751120Neonatal inflammatory skin and bowel disease1ORPHANET
TgeneERP44C0033578Prostatic Neoplasms1CTD_human
TgeneERP44C0376358Malignant neoplasm of prostate1CTD_human